A practical reference on lipolysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-17 and is reviewed periodically as new material appears.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
When the pipe surface is smooth (the "smooth pipe" curve in Figure 2), the friction factor's variation with Re can be modeled by the Kármán–Prandtl resistance equation for turbulent flow in smooth pipes with the parameters suitably adjusted
== Lithium-titanate battery == The lithium-titanate battery is a rechargeable battery that is much faster to charge than other lithium-ion batteries. It differs from other lithium-ion batteries because it uses lithium-titanate on the anode surface rather than carbon. This is advantageous because it does not create a solid electrolyte interface layer, which acts as a barrier to the ingress and egress of Li-ion to and from the anode. This allows lithium-titanate batteries to be recharged more quickly and provide higher currents when necessary. A disadvantage of the lithium-titanate battery is a much lower capacity and voltage than the conventional lithium-ion battery. The lithium-titanate battery is currently being used in battery electric vehicles and other specialist applications.
However, it is notable that the anabolic steroid methyltestosterone, which benorterone differs from in chemical structure only by the removal of a carbon atom in the B ring, is aromatized into the estrogen methylestradiol and has potent estrogenic activity. Estrogens are antigonadotropic similarly to androgens and progestogens and are likewise able to suppress testosterone levels. In accordance, the compound corresponding to what would be the aromatized form of benorterone, 17α-methyl-B-norestradiol, has been described and has been reported to possess estrogenic activity, although the aromatization of benorterone has not been assessed. A couple of studies found that prothrombin levels decreased by 50% in some patients treated with benorterone, although a causal relationship between this change and benorterone could not be shown.
It was announced in March 2017 that Galloway was standing as an independent candidate at the Manchester Gorton by-election, following the death of Sir Gerald Kaufman. Gorton had been one of Labour's safest seats. The by-election was cancelled following the announcement of the 2017 snap general election being held on 8 June. Galloway transferred his candidacy to the general election. Labour easily retained the seat; Galloway came a distant third with 6% of the vote. In the 2019 general election, Galloway contested the Parliamentary seat of West Bromwich East as an independent, describing himself as supportive of Corbyn's leadership and Brexit. He came sixth with 489 votes. On 14 December 2019, Galloway launched the Workers Party of Britain, which describes itself as "economically radical with an independent foreign policy" and "unequivocally committed to class politics". Galloway is the party's leader. In 2020 Galloway announced his intention to stand in an expected by-election in Rutherglen and Hamilton West, after sitting MP Margaret Ferrier breached COVID regulations, but the by-election was not held for 3 years. Galloway led All for Unity in the 2021 Scottish Parliament election and announced his intention to vote for the Conservative Party on the constituency vote, and for his party on the list vote. This contradicted other occasions when he said voting Conservative was something he would never consider. All for Unity received 23,299 votes in the election, or 0.9%, placing the party 7th nationally, with no seats.
Sources: en.wikipedia.org
Another Half-Life 2 episode was developed by Junction Point Studios, led by Warren Spector. The episode showed how the town of Ravenholm from Half-Life 2 became infested with headcrabs and zombies, with the return of the character of Father Grigori. It included a "magnet gun", which fired projectiles that magnetized metal surfaces and attracted objects and enemies, and was used for combat and puzzles. Junction Point worked on the game for a year, producing enough content to demonstrate one section, and a vertical slice that demonstrated the magnet gun. Valve lost interest in the project and Junction Point, who had been acquired by Disney Interactive Studios partway through, canceled it to instead develop Epic Mickey. Screenshots appeared in early 2017.
The HIC of leaf water is variable during the biosynthesis, and the enrichment in the whole leaf can be described by the equation, △Dleaf = △De × ([1 − e−p]/P) The typical δD of bulk plant is around −160‰, while δDs for cellulose and lignin are −110‰ and −70‰ respectively.
One of the most critical moments, which almost broke the consensus, was the discussion of article 27 related to the "religious question", but finally a consensual wording was reached in which the "freedom of education" and the "freedom of creation of educational centers" were recognized ─ and therefore, the right of the Catholic Church to maintain its religious centers ─ but it was admitted that "teachers, parents and, if applicable, students will intervene in the control and management of all the centers supported by the Administration with public funds" ─ that is, not only the state centers, but also the private or religious centers subsidized by the State. Other contentious issues were agreed upon by resorting to ambiguous wording of the articles, as occurred with abortion.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.